Brokerages predict that Cytosorbents Co. (NASDAQ:CTSO – Get Rating) will post $9.84 million in sales for the current quarter, Zacks reports. Five analysts have made estimates for Cytosorbents’ earnings. The lowest sales estimate is $9.16 million and the highest is $10.30 million. Cytosorbents posted sales of $10.60 million during the same quarter last year, which suggests a negative year over year growth rate of 7.2%. The company is expected to announce its next earnings report on Monday, January 1st.
On average, analysts expect that Cytosorbents will report full year sales of $44.46 million for the current year, with estimates ranging from $39.84 million to $46.50 million. For the next financial year, analysts forecast that the firm will report sales of $60.53 million, with estimates ranging from $56.51 million to $70.37 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Cytosorbents.
Cytosorbents (NASDAQ:CTSO – Get Rating) last posted its earnings results on Tuesday, March 8th. The medical research company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.08). The firm had revenue of $10.78 million for the quarter, compared to the consensus estimate of $9.72 million. Cytosorbents had a negative return on equity of 34.49% and a negative net margin of 56.90%.
Shares of NASDAQ CTSO traded up $0.05 during midday trading on Friday, hitting $2.93. 1,613 shares of the company’s stock were exchanged, compared to its average volume of 189,911. The business’s fifty day moving average price is $3.46 and its two-hundred day moving average price is $4.60. The company has a market cap of $127.47 million, a price-to-earnings ratio of -5.12 and a beta of 0.24. Cytosorbents has a 12-month low of $2.82 and a 12-month high of $9.80.
Several institutional investors have recently bought and sold shares of CTSO. BlackRock Inc. lifted its holdings in Cytosorbents by 2.8% in the 4th quarter. BlackRock Inc. now owns 2,631,210 shares of the medical research company’s stock worth $11,024,000 after buying an additional 72,418 shares during the period. Skylands Capital LLC increased its position in Cytosorbents by 5.9% during the 4th quarter. Skylands Capital LLC now owns 1,946,374 shares of the medical research company’s stock valued at $8,155,000 after purchasing an additional 108,833 shares during the period. Avenir Corp raised its holdings in Cytosorbents by 28.1% in the 4th quarter. Avenir Corp now owns 1,787,275 shares of the medical research company’s stock worth $7,489,000 after purchasing an additional 391,890 shares in the last quarter. Neuberger Berman Group LLC lifted its position in shares of Cytosorbents by 48.8% in the 3rd quarter. Neuberger Berman Group LLC now owns 1,260,574 shares of the medical research company’s stock worth $10,203,000 after purchasing an additional 413,485 shares during the period. Finally, Granahan Investment Management Inc. MA boosted its stake in shares of Cytosorbents by 15.0% during the 3rd quarter. Granahan Investment Management Inc. MA now owns 1,154,561 shares of the medical research company’s stock valued at $9,375,000 after purchasing an additional 151,015 shares in the last quarter. Institutional investors own 44.23% of the company’s stock.
About Cytosorbents (Get Rating)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant.
- Get a free copy of the StockNews.com research report on Cytosorbents (CTSO)
- OrganiGram’s Turnaround Begins To Blossom
- Three Dividend Stocks With Growth Potential
- Exelon Stock Still Has Extraordinary Upside
- Greenbrier Companies Stock has Green in its Future
- Insiders Are Selling Palo Alto Networks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.